Conduit Pharmaceuticals Inc (NASDAQ: CDT)’s stock price has increased by 2.48 compared to its previous closing price of 1.21. However, the company has seen a -5.34% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-20 that Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug development Sarborg delivers a prototype AI-product to Conduit’s Management team NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), is pleased to announce the completion of the initial milestones in Phase II of its strategic collaboration with AI and Cybernetics company, Sarborg Limited.
Is It Worth Investing in Conduit Pharmaceuticals Inc (NASDAQ: CDT) Right Now?
The stock has a 36-month beta value of 2.25.
The public float for CDT is 0.72M, and at present, short sellers hold a 31.06% of that float. On February 25, 2025, the average trading volume of CDT was 3.37M shares.
CDT’s Market Performance
The stock of Conduit Pharmaceuticals Inc (CDT) has seen a -5.34% decrease in the past week, with a -72.57% drop in the past month, and a -86.57% fall in the past quarter. The volatility ratio for the week is 17.30%, and the volatility levels for the past 30 days are at 24.81% for CDT. The simple moving average for the past 20 days is -33.12% for CDT’s stock, with a -97.75% simple moving average for the past 200 days.
CDT Trading at -75.74% from the 50-Day Moving Average
After a stumble in the market that brought CDT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.68% of loss for the given period.
Volatility was left at 24.81%, however, over the last 30 days, the volatility rate increased by 17.30%, as shares sank -62.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -86.76% lower at present.
During the last 5 trading sessions, CDT fell by -4.96%, which changed the moving average for the period of 200-days by -99.61% in comparison to the 20-day moving average, which settled at $1.8542. In addition, Conduit Pharmaceuticals Inc saw -81.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDT starting from Nirland Ltd, who sale 1,500,000 shares at the price of $0.10 back on Oct 03 ’24. After this action, Nirland Ltd now owns 8,400,000 shares of Conduit Pharmaceuticals Inc, valued at $156,450 using the latest closing price.
Nirland Ltd, the 10% Owner of Conduit Pharmaceuticals Inc, sale 1,368,991 shares at $0.10 during a trade that took place back on Oct 04 ’24, which means that Nirland Ltd is holding 7,031,009 shares at $140,458 based on the most recent closing price.
Stock Fundamentals for CDT
Current profitability levels for the company are sitting at:
- 0.02 for the present operating margin
- 0.54 for the gross margin
The net margin for Conduit Pharmaceuticals Inc stands at 0.02. The total capital return value is set at 0.02. Equity return is now at value -89.65, with -181.68 for asset returns.
Based on Conduit Pharmaceuticals Inc (CDT), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at 0.29. The debt to equity ratio resting at 0.95. The interest coverage ratio of the stock is -5.56.
Currently, EBITDA for the company is 266.46 million with net debt to EBITDA at 15.69. When we switch over and look at the enterprise to sales, we see a ratio of 0.35. The receivables turnover for the company is 6.01for trailing twelve months and the total asset turnover is 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.12.
Conclusion
To sum up, Conduit Pharmaceuticals Inc (CDT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
